Namita Thapar highlights GLP-1 medications or similar weight loss treatments have gained popularity, but their unauthorised ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Whoopi Goldberg has stunned in her latest looks showing off her 100+ pound weight loss after taking popular weight loss drug ...

Novo Nordisk (NVO) said Wednesday that it launched a direct-to-patient online pharmacy through which it will offer its weight loss injection at more than half the list price. The company's NovoCare ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Insulin resistance in T1D is more common than you think, and without early intervention, these patients face increased risks ...

A Stanford Medicine study taps artificial intelligence to find a naturally occurring molecule called a peptide that ...